Cargando…

Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy

BACKGROUND: Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear. METHODS: This study included a nintedanib pros...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahara, Masahiro, Oda, Keishi, Yamasaki, Kei, Kawaguchi, Takako, Sennari, Konomi, Noguchi, Shingo, Sakamoto, Noriho, Kawanami, Toshinori, Mukae, Hiroshi, Yatera, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704493/
https://www.ncbi.nlm.nih.gov/pubmed/31438928
http://dx.doi.org/10.1186/s12890-019-0918-3
_version_ 1783445511270825984
author Tahara, Masahiro
Oda, Keishi
Yamasaki, Kei
Kawaguchi, Takako
Sennari, Konomi
Noguchi, Shingo
Sakamoto, Noriho
Kawanami, Toshinori
Mukae, Hiroshi
Yatera, Kazuhiro
author_facet Tahara, Masahiro
Oda, Keishi
Yamasaki, Kei
Kawaguchi, Takako
Sennari, Konomi
Noguchi, Shingo
Sakamoto, Noriho
Kawanami, Toshinori
Mukae, Hiroshi
Yatera, Kazuhiro
author_sort Tahara, Masahiro
collection PubMed
description BACKGROUND: Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear. METHODS: This study included a nintedanib prospective study and historical control study. In the nintedanib prospective study, pulmonary artery systolic pressure (PASP) measured using transthoracic echocardiography was evaluated at six points during 48 weeks in 16 IPF patients in whom nintedanib was started. In the historical control study, adjusted annual change in PASP was compared between patients treated with (n = 16) and without (n = 15) nintedanib. RESULTS: In the nintedanib prospective study, the mean PASP at 48 weeks after starting nintedanib was significantly higher compared to that at baseline. When IPF patients were divided into two groups, IPF patients with or without long-term oxygen treatment (LTOT), mean PASP at 48 weeks was significantly higher than that at baseline only in IPF patients receiving LTOT (P = 0.001). In the historical control study, adjusted annual change in PASP in IPF patients treated with nintedanib was significantly lower than that in patients treated with no antifibrotic agents when considering patients without LTOT (0.26 mmHg vs 7.05 mmHg; P = 0.011). CONCLUSIONS: We found differential effects of nintedanib on PH between IPF patients with or without LTOT. Nintedanib may have a disadvantageous effect on PH in IPF patients with LTOT. Conversely, nintedanib treatment may be beneficial to PH in IPF patients without LTOT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-019-0918-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6704493
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67044932019-08-22 Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy Tahara, Masahiro Oda, Keishi Yamasaki, Kei Kawaguchi, Takako Sennari, Konomi Noguchi, Shingo Sakamoto, Noriho Kawanami, Toshinori Mukae, Hiroshi Yatera, Kazuhiro BMC Pulm Med Research Article BACKGROUND: Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear. METHODS: This study included a nintedanib prospective study and historical control study. In the nintedanib prospective study, pulmonary artery systolic pressure (PASP) measured using transthoracic echocardiography was evaluated at six points during 48 weeks in 16 IPF patients in whom nintedanib was started. In the historical control study, adjusted annual change in PASP was compared between patients treated with (n = 16) and without (n = 15) nintedanib. RESULTS: In the nintedanib prospective study, the mean PASP at 48 weeks after starting nintedanib was significantly higher compared to that at baseline. When IPF patients were divided into two groups, IPF patients with or without long-term oxygen treatment (LTOT), mean PASP at 48 weeks was significantly higher than that at baseline only in IPF patients receiving LTOT (P = 0.001). In the historical control study, adjusted annual change in PASP in IPF patients treated with nintedanib was significantly lower than that in patients treated with no antifibrotic agents when considering patients without LTOT (0.26 mmHg vs 7.05 mmHg; P = 0.011). CONCLUSIONS: We found differential effects of nintedanib on PH between IPF patients with or without LTOT. Nintedanib may have a disadvantageous effect on PH in IPF patients with LTOT. Conversely, nintedanib treatment may be beneficial to PH in IPF patients without LTOT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-019-0918-3) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-22 /pmc/articles/PMC6704493/ /pubmed/31438928 http://dx.doi.org/10.1186/s12890-019-0918-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tahara, Masahiro
Oda, Keishi
Yamasaki, Kei
Kawaguchi, Takako
Sennari, Konomi
Noguchi, Shingo
Sakamoto, Noriho
Kawanami, Toshinori
Mukae, Hiroshi
Yatera, Kazuhiro
Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
title Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
title_full Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
title_fullStr Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
title_full_unstemmed Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
title_short Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
title_sort temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704493/
https://www.ncbi.nlm.nih.gov/pubmed/31438928
http://dx.doi.org/10.1186/s12890-019-0918-3
work_keys_str_mv AT taharamasahiro temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT odakeishi temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT yamasakikei temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT kawaguchitakako temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT sennarikonomi temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT noguchishingo temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT sakamotonoriho temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT kawanamitoshinori temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT mukaehiroshi temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy
AT yaterakazuhiro temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy